CervoMed Inc.
$ 3.09
8.04%
11 Aug - close price
- Market Cap 38,685,000 USD
- Current Price $ 3.09
- High / Low $ 3.20 / 2.93
- Stock P/E N/A
- Book Value 1.70
- EPS -3.28
- Next Earning Report 2026-08-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.61 %
- ROE -1.08 %
- 52 Week High 11.25
- 52 Week Low 2.13
About
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. The company is headquartered in Boston, Massachusetts.
Analyst Target Price
$19.20
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-07 | 2026-05-18 | 2026-03-13 | 2025-11-07 | 2025-08-08 | 2025-05-12 | 2025-03-17 | 2024-11-12 | 2024-08-09 | 2024-05-14 | 2024-03-25 | 2023-11-13 |
| Reported EPS | -0.64 | -0.86 | -0.88 | -0.84 | -0.7 | -0.56 | -0.8 | -0.55 | -0.27 | -0.41 | -0.38 | 0.65 |
| Estimated EPS | -0.87 | -0.7929 | -0.7 | -0.64 | -0.62 | -0.6233 | -0.63 | -0.41 | -0.29 | -0.32 | -0.29 | -0.95 |
| Surprise | 0.23 | -0.0671 | -0.18 | -0.2 | -0.08 | 0.0633 | -0.17 | -0.14 | 0.02 | -0.09 | -0.09 | 1.6 |
| Surprise Percentage | 26.4368% | -8.4626% | -25.7143% | -31.25% | -12.9032% | 10.1556% | -26.9841% | -34.1463% | 6.8966% | -28.125% | -31.0345% | 168.4211% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-14 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.87 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CRVO
2026-08-10 21:09:51
Canaccord Genuity has reduced its target price for CERVOMED INC (CRVO.O) to $18 from the previous $27. This change reflects an updated assessment by the financial firm regarding the company's valuation. The article provides this information as a direct market update.
2026-08-10 21:09:51
CervoMed (NASDAQ: CRVO) reported its Q2 2026 financial results, detailing a net loss of $6.6 million and highlighting that its current cash of $24.9 million is expected to fund operations through Q3 2027. The company is prioritizing a strategic partnership to advance its lead drug, neflamapimod, into a Phase 3 trial for dementia with Lewy bodies (DLB), bolstered by a UK Innovation Passport Designation and new clinical data. Upcoming milestones include biomarker readouts for nfvPPA and the start of a Phase 2a trial for ALS.
2026-08-10 21:09:51
Canaccord Genuity lowered its price target on CervoMed Inc. to $18 from $27, citing uncertainty regarding funding for the company's lead drug candidate, neflamapimod, despite maintaining a Buy rating. The stock has seen a significant decline, but the firm believes it remains undervalued due to the large market opportunity in dementia with Lewy bodies. CervoMed has also presented new analyses of neflamapimod and completed enrollment for a Phase 2a study for another condition.
2026-08-09 21:09:51
CervoMed (NASDAQ:CRVO) is highlighted as a company that needs to carefully manage its cash burn, as it currently has only about 11 months of cash runway based on its June 2026 cash balance and annual burn rate of US$28 million. The article notes that the company's cash burn increased by 20% in the last year, and its US$28 million burn represents a significant 72% of its US$39 million market capitalization, indicating a high-risk situation with potential for extreme dilution if it needs to raise more capital. Investors are advised to pay close attention to the company's cash usage.
2026-08-08 01:10:40
CervoMed Inc. reported a net loss of ($6.57M) and ($0.64) EPS for the 2026 quarter, with grant revenue of $0, a significant drop from the prior year's $1.76M. The company completed $20.5M in financing for R&D, focusing on advancing neflamapimod clinical programs, particularly for DLB, and expects $24.9M in liquidity to fund operations into Q3 2027 while seeking Phase 3 partners.
2026-08-07 20:09:34
CervoMed Inc (CRVO) has an earnings forecast score of 8.00, placing it 171st in the Biotechnology & Medical Research industry. Analysts have set an average price target of $20.00, with a high of $31.00 and a low of $15.00. Based on ratings from 6 analysts, the overall recommendation for CRVO stock is "Buy."
